A minimally invasive treatment for enlarged prostate

Mr Hrishi Joshi, Consultant Urological Surgeon and Honorary Lecturer

Cardiff and Vale University Health Board

This Bevan Exemplar Project introduced UroLift as a minimally-invasive treatment for urinary tract symptoms from benign prostatic hyperplasia (BPH).


In men over the age of 50, around 1 in 3 have urinary symptoms. This is most commonly caused by an enlarged prostate, known as benign prostatic hyperplasia (BPH).

Men with moderate or severe symptoms are offered highly invasive surgical procedures; transurethral resection of the prostate (TURP) – cutting away or removing existing tissue.

Traditional surgical treatments pose a considerable burden on healthcare resources; pressures on bed availability and risk of cancellation; along with posing risks of post-operative complications (sexual, continence) and delayed recovery.

Diagrams of prostate, pre and post-procedure

UroLift is a new, 20 minute, minimally-invasive, day-case treatment alternative to surgery; lifting and holding the enlarged prostate tissue so it no longer blocks the urethra.

UroLift offers many benefits in a suitable patient population including rapid symptom relief with durable results and quality of life benefits to patients.



Next steps

The new service offering minimally invasive treatment has been satisfactorily implemented and can be adopted locally and nationally.

The UroLift is now part of the BPH task and finish group recommendation to the planned care board Wales for national adoption.

Anticipated benefits include:

Estimated saving of £1.5 million per year in reduced complications for Wales.

Estimated direct cost savings of over £25-30K a year in theatre time and bed stay (assuming 30 patients use the service).

Improved theatre efficiency, saving 1 theatre hour per case.

Improved bed capacity: no overnight stay or delayed transfer, at an estimate of 1200 inpatient bed days per year for Wales.

“Best thing ever, thank you.”


Part of cohort Bevan Exemplar Projects 2018-19